MOUNAINEER-03: Tucatinib in Combination with Trastuzumab and Chemotherapy in Patients With HER2+ CRC

Opinion
Video

Kristen K. Ciombor, MD, discussed the ongoing MOUNTAINEER-03 trial, a global Phase 3 study randomizing patients with untreated HER2-positive colorectal cancer patients to FOLFOX plus tucatinib/trastuzumab versus standard chemotherapy plus a biologic, which she said highlights the importance of upfront molecular testing and could change treatment.

Recent Videos
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Related Content
Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Unraveling The Benefits of Twice-Daily Chemoradiotherapy in LS-SCLC

Russ Conroy
October 3rd 2025
Article

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

A Variety of Treatment Options Are Becoming Available in CRC

A Variety of Treatment Options Are Becoming Available in CRC

ONCOLOGY Staff
December 31st 2023
Article

Kristen K. Ciombor, MD, MSCI, gives an overview of the current treatment landscape for patients with metastatic colorectal cancer.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to the Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 25th 2025
Podcast

Geraldine O’Sullivan Coyne, MD, PhD, MRCPI, discusses how the START center may expand access to novel therapies for patients who reside in a community setting.

Cabozantinib plus nivolumab and ipilimumab appears to improve progression-free survival vs cabozantinib alone among patients with metastatic soft-tissue sarcoma in a phase 2 trial.

Cabozantinib Combo Yields Disease Control in Metastatic Soft Tissue Sarcoma

Brielle Benyon
June 5th 2023
Article

Cabozantinib plus nivolumab and ipilimumab appears to improve progression-free survival vs cabozantinib alone among patients with metastatic soft-tissue sarcoma in a phase 2 trial.

Collaboration in kidney cancer palliative care and integrative medicine programs underscores the current development of University Hospitals’ integrative oncology wing.

Expert Outlines Collaborative Integrative Oncology Plans in Kidney Cancer

Santosh Rao, MD
April 10th 2023
Article

Collaboration in kidney cancer palliative care and integrative medicine programs underscores the current development of University Hospitals’ integrative oncology wing.